Showing results (41-50 of 93) with videos related to

Sort By:
Pageof 10
Bone Marrow Transplantation|March 6, 2023
Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity SurveyJakob R Passweg, Helen Baldomero, Fabio Ciceri, et al.
Bone Marrow Transplantation|March 4, 2024
Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMTJakob R Passweg, Helen Baldomero, Fabio Ciceri, et al.
Blood Advances|September 23, 2022
Health-related quality of life with lisocabtagene maraleucel vs standard of care in relapsed or refractory LBCLJeremy S Abramson, Patrick B Johnston, Manali Kamdar, et al.
Bone Marrow Transplantation|February 23, 2022
Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity surveyJakob R Passweg, Helen Baldomero, Christian Chabannon, et al.
Bone Marrow Transplantation|February 24, 2021
Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 yearsJakob R Passweg, Helen Baldomero, Christian Chabannon, et al.
Blood|December 21, 2022
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM studyJeremy S Abramson, Scott R Solomon, Jon Arnason, et al.
Blood Advances|August 30, 2024
Autologous stem cell transplantation in T-cell/histiocyte-rich large B-cell lymphoma: EBMT Lymphoma Working Party studySimon Renders, Maud Ngoya, Herve Finel, et al.
Bone Marrow Transplantation|March 27, 2023
Practice harmonization workshops of EBMT: an expert-based approach to generate practical and contemporary guidelines within the arena of hematopoietic cell transplantation and cellular therapyIbrahim Yakoub-Agha, Raffaella Greco, Francesco Onida, et al.
Haematologica|March 13, 2016
Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMTBipin N Savani, Myriam Labopin, Nicolaus Kröger, et al.
The Lancet. Haematology|March 5, 2021
Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trialFabian Frontzek, Marita Ziepert, Maike Nickelsen, et al.
Pageof 10